Introduction
============

Intravenous immunoglobulin (IVIG) has been widely used as an antibody replacement or an "immunomodulatory agent" for indications in hematology, neurology, immunology, rheumatology, dermatology, nephrology, and ophthalmology.[@b1-ceor-10-001],[@b2-ceor-10-001] While the clinical indications for using IVIG are expanding,[@b3-ceor-10-001]--[@b6-ceor-10-001] its administration may lead to considerable side effects and potential adverse events (AEs).[@b3-ceor-10-001] In addition, IVIG is expensive and thus requires judicious utilization. The annual cost of IVIG treatment has been estimated to exceed US\$30,000 per patient depending on dosing, indications, and length of therapy.[@b7-ceor-10-001]--[@b10-ceor-10-001] Given the overall potential burden of Ig costs, considerations for cost containment are essential.

Clinical outcomes
-----------------

IVIG has been licensed by the US Food and Drug Administration for prevention of infection in various immunodeficiency diseases that cause susceptibility to recurrent, severe, or usual infections.[@b3-ceor-10-001],[@b4-ceor-10-001] Infection rates were chosen as one of the primary clinical outcome measures for our study. AEs were also included, since IVIG administration often results in mild AEs and more rarely in severe AEs, though its safety profile is well established.[@b11-ceor-10-001]--[@b15-ceor-10-001]

Infections
----------

In the US, about 25--30% of IVIG grams are used for the treatment of primary immunodeficiency disorder (PID), which is characterized by recurrent infections. Common variable immunodeficiency is the most common type of PID.[@b16-ceor-10-001]--[@b18-ceor-10-001] While there is extensive experience with the efficacy of IVIG in common variable immunodeficiency and related PID, there are increasing options for providing therapy, including dose, frequency, and site of care. IVIG therapy dose and residual "trough" IgG levels have been in aggregate correlated with infectious outcomes,[@b19-ceor-10-001]--[@b21-ceor-10-001] and current practice tends to focus upon individualizing the dosing approach to any given patient.

Adverse events
--------------

AEs are common in IVIG therapy. They can be classified as mild (eg, headache, flushing, shivering, itching, urticaria, anxiety, dizziness), moderate (eg, chest pain, wheezing, blood pressure fluctuations, mild reactions becoming worse), or severe (eg, severe headache, aseptic meningitis, renal dysfunction, anaphylaxis, thromboembolic event, moderate reaction persisting or becoming worse) reactions.[@b19-ceor-10-001]--[@b23-ceor-10-001] A number of studies in the US and other countries have examined the incidence of IVIG-related AEs.[@b3-ceor-10-001],[@b19-ceor-10-001]--[@b21-ceor-10-001],[@b23-ceor-10-001]--[@b27-ceor-10-001] The incidence rates varied widely across studies (21.4--44% of patients; 2.4--12.8% of infusions).[@b3-ceor-10-001],[@b19-ceor-10-001]--[@b21-ceor-10-001],[@b23-ceor-10-001]--[@b27-ceor-10-001] The majority of AEs reported were mild (non-severe).[@b3-ceor-10-001],[@b19-ceor-10-001],[@b24-ceor-10-001] Most mild reactions were able to be reversed by slowing or stopping the infusion for 15--30 minutes.[@b3-ceor-10-001] Severe AEs were rare: 0--1.3% of infusions or 0--3.6% of treatment courses.[@b19-ceor-10-001],[@b21-ceor-10-001],[@b23-ceor-10-001] Headache was reported as the most common type of AE in some studies,[@b23-ceor-10-001],[@b25-ceor-10-001] and patients who received premedication had significantly reduced incidence of AEs (18.2% vs 29.3%, *P*=0.02).[@b24-ceor-10-001]

Economic outcomes
-----------------

Few studies have examined economic outcomes associated with Ig therapy, despite the increasing focus on management of health care cost.[@b10-ceor-10-001],[@b28-ceor-10-001],[@b29-ceor-10-001] One study in the US found that the annual costs of IVIG therapies for treating chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy were \>\$50,000 per patient,[@b10-ceor-10-001] and annual mean costs for treating a cohort of mucous membrane pemphigoid, ocular cicatricial pemphigoid, bullous pemphigoid, and pemphigus vulgaris patients with IVIG were \$65,190 (\$37,271--\$118,232) in another US study.[@b29-ceor-10-001] Ig drug costs have been identified as the main cost drivers of IVIG therapy in several studies from various countries (Canada, Italy, and Germany).[@b28-ceor-10-001],[@b30-ceor-10-001]--[@b32-ceor-10-001]

Ig clinical management
----------------------

Given the current focus on evidence-based medicine and health care cost containment, appropriate clinical management to assure the safe and effective administration of IVIG products is desirable. Accordingly, a "high-touch" clinical management program for patients with IVIG therapy was developed by a US home infusion and specialty pharmacy. The program provided IVIG infusion in a patient's home or at ambulatory infusion suites. It consisted of a comprehensive care model that included a pre-infusion risk assessment by a pharmacist, infusion monitoring by an Ig-specialized registered nurse (RN), regular clinical follow-up with a patient by a pharmacist that was communicated to physicians for expedient resolution of any clinical issues, and financial consultations.

Site of care
------------

Few studies in the US have compared site of care (ie, place of service), such as hospital inpatient, hospital outpatient, physician office, community infusion center, and patient home. Small studies comparing two care sites have identified no differences in infection or related clinical outcomes, although some differences in quality of life and cost have emerged.[@b33-ceor-10-001],[@b34-ceor-10-001] Further understanding of the clinical and economic advantages and disadvantages of all available sites of care is needed. Regardless of site of care, expert clinical practice is essential to ensure safe administration of IVIG[@b3-ceor-10-001],[@b20-ceor-10-001],[@b35-ceor-10-001] and avoid adverse reactions.[@b20-ceor-10-001]

Study objective
---------------

This study evaluated a national home infusion specialty pharmacy clinical management program on economic and clinical outcomes of IVIG patients. We hypothesized that AEs and infection rates, as well health costs, could be lower through this patient management model compared to the outcomes of other care models.

Ethics approval
---------------

This research was approved by Quorum IRB (28495/1) with a waiver of informed consent, as well as a complete waiver of Health Insurance Portability and Accountability Act authorization.

Materials and methods
=====================

We conducted a retrospective cohort study to compare the clinical and economic outcomes of patients who received IVIG and managed by an Ig clinical management program with matched controls in the PharMetrics Plus (PMTX+) database, a US-based administrative claims database with adjudicated medical and pharmacy claims for more than 150 million unique enrollees since 2006.

Ig clinical management model
----------------------------

This IVIG patient care model provided individualized patient care and clinical management by qualified health care professionals. These services included the following: pre-infusion clinical evaluation -- evaluation for comorbidities affecting the risk of adverse drug reactions (ADRs), coordination with the prescribing clinician for individualized infusion plans to avoid ADRs and patient education to address concerns proactivelyclinical management of infusion by RNs -- individualized infusion rate protocols with clinical monitoring before, during, and after infusion; patient education regarding Ig; expectations of treatment; and potential AEsregular clinical follow-up with a patient by a pharmacist that was communicated to the prescribing clinician -- minimally quarterly contact (always after the first visit, a monthly option is also provided) to assess adherence and ADR management, disease-specific patient-reported outcome measures (quarterly report), and dose adjustment

The care team also provided patient consultation on insurance coverage and financial assistance.

Data source and study population
--------------------------------

The data used in this study was from the PMTX+ database, from which the dependent outcomes and covariables for both intervention and control groups were derived. This database is a large longitudinal repository of adjudicated medical and pharmacy claims of more than 150 million unique, commercially insured members throughout the US since 2006.

The same inclusion and exclusion criteria were used for the intervention and control groups. Included in the study were patients who had received at least one claim (prescription or administration procedure) for IVIG therapy between September 1, 2011 and June 30, 2013, had continuous eligibility in the PMTX+ database for a minimum of 6 months prior to and 12 months after the date they had received the first IVIG therapy in the study period (the index date), and had at least four IVIG claims in the 12-month post-index period and one claim of IVIG during or after month 6. Both intervention and control cohorts excluded patients who were administered intramuscular immunoglobulin or subcutaneous immunoglobulin during the period, who had incomplete or invalid data records, or if they were prescribed products that can be administered subcutaneously or intravenously (ie, Gammagard liquid, Gamunex-C, and Gammaked), unless they had an administration code (ie, J1561, J1569) observed within 7 days of the claim date. All inclusion and exclusion criteria can be found in [Table S1](#SD1-ceor-10-001){ref-type="supplementary-material"}.

The intervention group was identified by linking patients from the national home infusion specialty pharmacy to the PMTX+ database. All patients at the national home infusion specialty pharmacy were managed by the Ig clinical management program, which was administered across multiple locations in the US. None of the patients opted out unless their claims could not be identified in the databases.

All patients were categorized by whether they had an IVIG-treatable autoimmune disease, a non-IVIG-treatable autoimmune disease, or a non-autoimmune disease ([Table S2](#SD2-ceor-10-001){ref-type="supplementary-material"}). Within each autoimmune-disease category, the control group was selected from patients who were not in the program and matched to the intervention group using a 1:4 greedy propensity score without replacement.[@b36-ceor-10-001] Covariates in the propensity score model were age at index date, sex, proximity to immunology centers of excellence ([Table S3](#SD3-ceor-10-001){ref-type="supplementary-material"}), geographic region, Charlson Comorbidity Index score, and 6-month pre-index total health care costs ([Table 1](#t1-ceor-10-001){ref-type="table"}).

Clinical outcomes
-----------------

Primary clinical outcomes included infection and infusion-related AE rates. Infections were categorized into three groups: serious bacterial infections (SBIs), other infections, and all infections (both SBIs and other infections).[@b14-ceor-10-001],[@b15-ceor-10-001],[@b37-ceor-10-001]--[@b41-ceor-10-001] AEs were categorized into four groups: common AEs, serious AEs, and mild, less common AEs (both subjective and objective) ([Table S3](#SD3-ceor-10-001){ref-type="supplementary-material"}). Infections and AEs were reported as both patient counts by events of interest and as rates (number of events per patient per year).

Economic outcomes
-----------------

The primary economic outcome was direct medical costs per person during the study period (12 months post-index date). Total health care costs and segregated cost categories, inpatient, emergency center, outpatient, and total pharmacy claims were reported. All patients in the cohort were included for calculating total health care cost. The allowed amount of the claim was used to determine direct costs, which was defined as the amount the health plan allowed for a particular service, and included both the plan amount paid and member liability (ie, copayment, deductible, and coinsurance). These fully adjudicated claims were inflation-adjusted to 2014 prices using the medical care component of the US Consumer Price Index for all urban consumers. When appropriate, costs that were considered directly related to the drug or administration of the drug were broken down based on Healthcare Common Procedure Coding System (HCPCS), Current Procedural Terminology (CPT), or National Drug Codes. Specifically, Ig-related costs were reported for total allowable costs and total outpatient costs (based on HCPCS/CPT codes). Inpatient/outpatients costs were capped at five times the standard deviation (SD), in order to mitigate outlier effects for both intervention and control groups.

Statistical analyses
--------------------

We compared baseline characteristics between the two groups using *c*^2^ or Fisher's exact test for categorical variables and Student's *t*-test for continuous variables. Categorical measures were reported as the number of cases and percentage of total patients observed in each category, and both mean and SD/confidence intervals (CIs) were reported for continuous variables. Clinical and economic outcomes were analyzed using generalized estimation equation (GEE) models with log-link, negative-binomial distributions. The unstructured correlation matrix was applied or compound symmetry used if the model did not converge. For the clinical model, the adjusted event rate was reported and the models adjusted for program-management model, number of Ig administrations, place of service (eg, hospital, home, clinic), diabetes (yes/no), and renal disease (yes/no). The program-management variable adjusted for changes in how the program was administered over the 3-year study period across the US. For example, the frequency of clinical assessments increased for the intervention group over time. For the economic model, adjusted mean costs used were adjusted by program management model, place of service, and number of Ig administrations. The proportion of patients with AEs was compared between intervention and control groups using *c*^2^ or Fisher's exact test. Unadjusted results were presented if the GEE model did not converge. All analyses were performed at a patient level using SAS 9.2 (SAS Institute, Cary, NC, USA). *P*\<0.05 was considered statistically significant.

Results
=======

To evaluate the impact of this "high-touch" clinical management program, both clinical and economic outcomes were compared between patients within the program and their matched controls. Prior to propensity score matching, there were 274 and 4,010 eligible patients in the intervention and control groups, respectively. Before matching, patient geographic distribution and access to immunology expertise centers were significantly different between the two groups, whereas no significant differences were found for age, sex, or autoimmune disease status. After propensity score matching, the 242 and 968 patients remaining in the intervention and control groups, respectively, had similar baseline characteristics across all domains, including cost prior to intervention ([Table 1](#t1-ceor-10-001){ref-type="table"}).

After the intervention, there were a few differences worth noting. While most AE and infection outcomes were not statistically significantly different, the proportion of patients who had SBIs was significantly lower in the intervention group compared to the matched controls (4.13% vs 7.75%, *P*=0.05). The SBI rate (events per patient per year) was also much lower among managed patients and close to significance (0.12 vs 0.45, *P*=0.07; [Table 2](#t2-ceor-10-001){ref-type="table"}).

Considerably lower cost was achieved for managed patients ([Table 3](#t3-ceor-10-001){ref-type="table"}). The annual mean total allowable cost of patients in the clinical management program was \$26,522 (20%) lower compared to the annual mean cost of matched controls (*P*=0.002), with the difference in mean Ig-related total allowable costs \$17,495 (annual mean cost of intervention vs control groups \$64,332 vs \$81,827, *P*=0.001). A major contribution to this difference (\$17,269) was Ig-related total outpatient cost (intervention vs control groups: \$64,080 vs \$81,349, *P*=0.001). Though not statistically significant, annual differences in total mean inpatient and pharmacy costs were \$5,356 and \$1,517, respectively. In contrast, the total emergency center care costs were slightly higher for patients in the IVIG clinical management program, but the difference was not significant (*P*=0.107).

Discussion
==========

IVIG is standard therapy for many immunologic diseases. In recent years, alternative sites of care for IVIG infusion have emerged, including infusion in a patient's home or at an ambulatory infusion suite, compared to more traditional sites of care, such as a hospital or a physician's office.[@b6-ceor-10-001],[@b42-ceor-10-001]

Due to the complexity of immunoglobulin administration and its known potential for causing AEs, safety is a major concern, especially in settings outside hospitals or hospital infusion centers. While IVIG infusion is clinically complex, several studies have demonstrated the safety of administration of IVIG at home or in ambulatory infusion settings.[@b26-ceor-10-001],[@b43-ceor-10-001]--[@b45-ceor-10-001] Providers and physicians continue to develop and optimize clinical care models to provide the best outcomes while minimizing health care expenditures. The results of this study suggested that a clinical care model drives comparable clinical outcomes when compared to a diverse population receiving IVIG. AE rates and non-serious infection rates in the intervention group were comparable, while SBI rates and the proportion of patients who had SBIs were either significantly lower or very close to being significantly lower in the intervention group. This may be attributable to the individualized infusion services provided by the Ig-trained RNs and pharmacists in this care model. It was difficult to compare our findings with AE rates stated in the existing literature, due to differences in Ig dosages, diversity of diagnoses, and the scope and definition of AEs and infections. When one considers AE rates in licensing materials (package inserts) from IVIG products, those identified in the present work were generally in line with existing/expected experience.[@b34-ceor-10-001] The major exception was common, mild AEs, which were low in both populations, but this could have been due to differences in reporting these occurrences in a trial study vs real-world practice.

This study also revealed lower direct health care expenditure in the intervention group compared to the control group. The majority of the difference in total adjusted allowable cost between the two groups was in Ig-related outpatient costs (\$17,269, 65% of cost difference). The IVIG treatment cost variations in this study and two other US studies cited in the introduction session could be attributed to cost inflation, place of service, disease scope, and dosage range of Ig therapies. Even when Ig-related costs were removed, cost differences remained in the intervention group when compared to controls. This difference could be ascribed to lower medication costs related to site of care; in other words, the same drug is reimbursed differently across sites of care.[@b46-ceor-10-001],[@b47-ceor-10-001] With the rising demand for accessible high-quality care at lower overall cost, this patient-centered clinical management model may show the ability to help achieve these goals in IVIG treatment.

Limitations
-----------

Many of the limitations in this study were similar to many other retrospective observational studies using administrative claims data. For instance, the population of patients selected for one particular treatment over another may have different characteristics (channeling bias). The medical billing codes used to indicate diagnoses and procedures may be subject to non-clinical influences. Some of these differences can often be measured (such as age and autoimmune disease status), and thus were controlled for in this study. Others were unknown or not measurable. In addition, this study was unable to specify if any clinical care model was applied to any patient in the control group. Because our study period covered 3 years, changes in the program model were inevitable, although we tried to control for such changes by adding the program management model variable to our regression models. While there was careful matching of the intervention and control groups in the pre-intervention period, the comparison may be skewed by physicians maintaining more fragile patients at inpatient and outpatient settings for treatment, which would lead to a bias in health care-related expenses in the control group. That said, we controlled for pre-intervention costs via propensity score matching. Importantly, the cost advantage of this care model was maintained, even when the differing drug cost was removed as a factor. Future studies could and perhaps should focus more specifically upon comparing specific care models within individual sites of care. This, however, represents a first step in generating the motivation for these questions.

Implications for clinical care and future research
==================================================

In aggregate, though there were a few notable clinical benefits, clinical outcomes were similar between patients in this care model and the matched control group, which likely represented various types of care models. However, given the significant economic advantage shown here, the provision of therapy at home using this type of care model should be a consideration for patients, providers, and payers. Since it was difficult to draw strong conclusions from this initial study, further research will be needed to identify exactly which type of patients may benefit most and exactly what advantages this robust clinical care model may offer in comparison with other programs. Appreciating that the site of care decision for patients is complex, we are hopeful that research will help identify how to utilize advantages and avoid disadvantages to achieve the best clinical outcomes and cost savings for patients.

Supplementary materials
=======================

###### 

Study population attrition

  Criterion                                                                                              Intervention   Control            
  ------------------------------------------------------------------------------------------------------ -------------- --------- -------- -------
  Patients received IVIG during 6-month pre-index period (September 1, 2011 to June 30, 2013)            595            100%      11,918   100%
  AND met continuous enrollment in PMTX+ database for a minimum of 6 months prior to index date          435            73.1%     9,206    77.2%
  AND met continuous enrollment criteria in PMTX+ database for a minimum of 12 months after index date   354            59.5%     6,599    55.4%
  AND with at least four claims of index IG in 12-month post-index period                                312            52.4%     5,017    42.1%
  AND with one claim of index IVIG on or after month 6 (ie, after day 150 from index)                    282            47.4%     4,190    35.2%
  AND without IMIG (exclusion criteria)                                                                  282            47.4%     4,190    35.2%
  AND not receiving both SCIG and IVIG during 12-month post-index period                                 274            46.1%     4,048    34%
  AND with complete data and valid data                                                                  274            46.1%     4,010    33.6%
  Post 1:4 propensity score matching                                                                     242            40.7%     968      8.1%

**Abbreviations:** IVIG, intravenous Ig; PMTX, PharMetrics; IMIG, intramuscular immunoglobulin; SCIG, subcutaneous immunoglobulin.

###### 

Classification of autoimmune disease covariates

                                                                                                                                                      ICD9-CM                      IVIG-treatable autoimmune disease   Not IVIG-treatable autoimmune disease   Not autoimmune disease
  --------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- ----------------------------------- --------------------------------------- ------------------------
  Common variable immunodeficiency                                                                                                                    279.0X                                                                                                   Yes
  Immunodeficiency diseases                                                                                                                           279.1X, 279.2, 279.3                                                                                     Yes
  Behçet's syndrome                                                                                                                                   136.1                        Yes                                                                         
  Post-polio syndrome                                                                                                                                 138                          Yes                                                                         
  Autoimmune cytopenia                                                                                                                                238.7                        Yes                                                                         
  Hashimoto's thyroiditis and thyroiditis with hyperthyroidism                                                                                        245.2                        Yes                                                                         
  Autoimmune diabetes mellitus                                                                                                                        250.01, 250.03               Yes                                                                         
  Autoimmune disease not elsewhere classified                                                                                                         279.4X (not 279.41)          Yes                                                                         
  Graft-versus-host disease                                                                                                                           279.5                        Yes                                                                         
  Hemolytic anemia, autoimmune                                                                                                                        283                          Yes                                                                         
  Autoimmune hemophilia                                                                                                                               286.52                       Yes                                                                         
  Henoch--Schönlein purpura                                                                                                                           287                          Yes                                                                         
  Idiopathic thrombocytopenic purpura                                                                                                                 287.31                       Yes                                                                         
  Post-transfusion purpura                                                                                                                            287.41                       Yes                                                                         
  Autoimmune neutropenia                                                                                                                              288.09                       Yes                                                                         
  Macrophage-activation syndrome                                                                                                                      288.4                        Yes                                                                         
  Acute disseminated encephalomyelitis, autoimmune encephalopathy, limbic encephalitis, Rasmussen's syndrome, demyelinating brain-stem encephalitis   323.81                       Yes                                                                         
  Alzheimer's disease                                                                                                                                 331                          Yes                                                                         
  Stiff-person syndrome                                                                                                                               333.91                       Yes                                                                         
  Cerebellar ataxia, opsoclonus--myoclonus syndrome, post-infectious, paraneoplastic cerebellar degeneration                                          334.2, 334.3                 Yes                                                                         
  Paraproteinemic neuropathy                                                                                                                          337.00, 337.09, 356.8        Yes                                                                         
  IgM antimyelin-associated glycoprotein paraprotein-associated peripheral neuropathy                                                                 337.1                        Yes                                                                         
  Multiple sclerosis, relapsing--remitting                                                                                                            340                          Yes                                                                         
  Epilepsy, intractable childhood                                                                                                                     345.61                       Yes                                                                         
  Narcolepsy with cataplexy                                                                                                                           347.01                       Yes                                                                         
  Lumbosacral or brachial plexitis                                                                                                                    353.0, 353.1                 Yes                                                                         
  Chronic demyelinating polyneuropathy                                                                                                                356.4                        Yes                                                                         
  Guillain--Barré syndrome                                                                                                                            357                          Yes                                                                         
  Multifocal motor neuropathy                                                                                                                         357.89                       Yes                                                                         
  Myasthenia gravis                                                                                                                                   358                          Yes                                                                         
  Lambert--Eaton myasthenic syndrome                                                                                                                  358.3                        Yes                                                                         
  Necrotizing autoimmune myopathy                                                                                                                     359.81                       Yes                                                                         
  Uveitis, autoimmune                                                                                                                                 360.19                       Yes                                                                         
  Grave's ophthalmopathy (thyrotoxic exophthalmos)                                                                                                    376.21                       Yes                                                                         
  Autoimmune optic neuropathy                                                                                                                         377.49, 377.30               Yes                                                                         
  Brown--Vialetto--van Laere syndrome                                                                                                                 389.1                        Yes                                                                         
  Cerebral infarctions with antiphospholipid antibodies                                                                                               434.01, 434.11, 434.91       Yes                                                                         
  Polyarteritis nodosa                                                                                                                                446                          Yes                                                                         
  Kawasaki disease                                                                                                                                    446.1                        Yes                                                                         
  Thrombotic thrombocytopenic purpura                                                                                                                 446.6                        Yes                                                                         
  Antineutrophil antibody syndrome                                                                                                                    447.6                        Yes                                                                         
  Inflammatory bowel disease                                                                                                                          555.0, 555.1, 555.2, 555.9   Yes                                                                         
  Autoimmune chronic active hepatitis                                                                                                                 571.42                       Yes                                                                         
  Antiphospholipid antibody syndrome in pregnancy                                                                                                     649.3                        Yes                                                                         
  Pemphigus foliaceus, pemphigus vulgaris, pemphigus, paraneoplastic                                                                                  694.4                        Yes                                                                         
  Bullous pemphigoid                                                                                                                                  694.5                        Yes                                                                         
  Cicatricial pemphigoid                                                                                                                              694.6                        Yes                                                                         
  Scleromyxedema                                                                                                                                      701.8                        Yes                                                                         
  Chronic urticaria                                                                                                                                   708.1, 708.8                 Yes                                                                         
  Systemic lupus                                                                                                                                      710                          Yes                                                                         
  Systemic sclerosis (scleroderma)                                                                                                                    710.1                        Yes                                                                         
  Sjögren's syndrome (sicca syndrome)                                                                                                                 710.2                        Yes                                                                         
  Dermatomyositis                                                                                                                                     710.3                        Yes                                                                         
  Polymyositis                                                                                                                                        710.4                        Yes                                                                         
  Mixed connective-tissue disease                                                                                                                     710.8                        Yes                                                                         
  Unspecified diffuse connective-tissue disease                                                                                                       710.9                        Yes                                                                         
  Rheumatoid arthritis, severe                                                                                                                        714                          Yes                                                                         
  Felty's syndrome                                                                                                                                    714.1                        Yes                                                                         
  Juvenile idiopathic arthritis                                                                                                                       714.3                        Yes                                                                         
  Juvenile idiopathic arthritis                                                                                                                       714.31                       Yes                                                                         
  HTLV1-associated myelopathy                                                                                                                         721.1, 721.4, 721.91         Yes                                                                         
  Acute idiopathic dysautonomia                                                                                                                       742.8                        Yes                                                                         
  Chronic bullous disease of childhood, epidermolysis bullosa acquisita                                                                               757.39                       Yes                                                                         
  Fetomaternal alloimmune thrombocytopenia                                                                                                            776.1                        Yes                                                                         
  Sarcoidosis                                                                                                                                         135                                                              Yes                                     
  Grave's disease                                                                                                                                     242                                                              Yes                                     
  Addison's disease, autoimmune                                                                                                                       255.41                                                           Yes                                     
  Autoimmune polyglandular syndrome, type I                                                                                                           258.01                                                           Yes                                     
  Autoimmune polyglandular syndrome, type II                                                                                                          258.02, 258.03                                                   Yes                                     
  Pernicious anemia                                                                                                                                   281                                                              Yes                                     
  Encephalomyelitis                                                                                                                                   323.9                                                            Yes                                     
  Retinopathy                                                                                                                                         362.1                                                            Yes                                     
  Thromboangiitis obliterans                                                                                                                          443.1                                                            Yes                                     
  Churg--Strauss disease, Wegener's granulomatosis                                                                                                    446.4                                                            Yes                                     
  Temporal arteritis                                                                                                                                  446.5                                                            Yes                                     
  Takayasu's arteritis                                                                                                                                446.7                                                            Yes                                     
  Autoimmune chronic active hepatitis                                                                                                                 571.49                                                           Yes                                     
  Primary biliary sclerosis                                                                                                                           571.6                                                            Yes                                     
  Sclerosing cholangitis                                                                                                                              576.1                                                            Yes                                     
  Gluten-sensitive enteropathy                                                                                                                        579                                                              Yes                                     
  Infertility, immunomediated                                                                                                                         628.8                                                            Yes                                     
  Pemphigoid gestationis                                                                                                                              646.8                                                            Yes                                     
  Dermatitis herpetiformis                                                                                                                            694.2                                                            Yes                                     
  Linear IgA disease                                                                                                                                  694.8                                                            Yes                                     
  Erythema nodosa                                                                                                                                     695.2                                                            Yes                                     
  Psoriasis                                                                                                                                           696.1                                                            Yes                                     
  Alopecia, autoimmune                                                                                                                                704                                                              Yes                                     
  Vitiligo                                                                                                                                            709.01                                                           Yes                                     
  Other rheumatoid arthritis with visceral or systemic involvement                                                                                    714.2                                                            Yes                                     
  Rheumatoid lung                                                                                                                                     714.81                                                           Yes                                     
  Other specified inflammatory polyarthropathies                                                                                                      714.89                                                           Yes                                     
  Unspecified inflammatory polyarthropathy                                                                                                            714.9                                                            Yes                                     
  Ankylosing spondylitis                                                                                                                              720                                                              Yes                                     

**Abbreviations:** HTLV1, Human T-lymphotropic virus 1; IVIG, intravenous immunoglobulin.

###### 

Clinical outcomes

  Clinical outcome                                                                                              Diagnosis                                                                                                  ICD9-CM
  ------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- -------------------------------
  Serious bacterial infections                                                                                  Bacterial pneumonia                                                                                        482.XX
  Visceral abscess                                                                                              324.X, 478.24. 513.0, 567.22, 567.38, 572.0, 590.2                                                         
  Septicemia                                                                                                    995.91, 995.92, 038.xx, 790.7, 785.52                                                                      
  Bacterial meningitis                                                                                          320.X, 321.X, 322.X, 047.X, 003.21, 036.0                                                                  
  Osteomyelitis/septic arthritis                                                                                711.0X, 730.0X                                                                                             
  Other infections                                                                                              Conjunctivitis                                                                                             372.00, 372.05, 372.3, 372.03
  Acute bronchitis                                                                                              466                                                                                                        
  Acute otitis                                                                                                  382.0, 382.0X, 382.4, 382.9.                                                                               
  Pyoderma/cellulitis/subcutaneous abscess                                                                      686.XX, 682.XX                                                                                             
  Mastoiditis                                                                                                   383.XX                                                                                                     
  Sinusitis                                                                                                     461.X, 473.X                                                                                               
  URI (added on February 1, 2015                                                                                465.8, 465.9                                                                                               
  Common AEs                                                                                                    Abdominal pain                                                                                             789.XX, 789.6
  Fever/pyrexia                                                                                                 780.60, 780.62, 780.66                                                                                     
  Nausea                                                                                                        787.02                                                                                                     
  Asthenia/other malaise and fatigue                                                                            780.79                                                                                                     
  Headache/acute migraine                                                                                       784.0, 339.00, 339.01, 339.43, 339.85, and 346.XX with the exceptions of 346.40, 346.41, 346.42, 346.43;   
  Myalgia                                                                                                       729.1                                                                                                      
  Rash/local reaction: burning or itching                                                                       782.1                                                                                                      
  Serious rare AEs                                                                                              Anaphylaxis/anaphylactoid reaction/anaphylactic shock                                                      995.0, 999.41, 999.49
  Pulmonary edema                                                                                               518.4                                                                                                      
  Embolism                                                                                                      444.X, 415.19, 445.x                                                                                       
  Seizure                                                                                                       345.0X, 345.1X, 345.2X, 345.3X, 345.4X, 345.5X, 345.8X, 345.9X, 780.39                                     
  Aseptic meningitis                                                                                            322.9                                                                                                      
  Transfusion-related acute lung injury                                                                         518.7                                                                                                      
  "Serum sickness"                                                                                              999.51, 999.59                                                                                             
  Acute renal failure/anuria/renal tubular necrosis/blood creatinine increased/blood urea increase              584.XX                                                                                                     
  Thrombotic complications                                                                                      453.9                                                                                                      
  Dermatitis, bullous/exfoliative/epidermal                                                                     694                                                                                                        
  Hepatitis/acute hepatitis (uninfectious)/hepatic dysfunction/hepatic failure/hepatocellular damage/jaundice   573.3, 070.XX                                                                                              
  Neurodegeneration                                                                                             294.1                                                                                                      
  Neurological illness                                                                                          357.9 and 348.9                                                                                            
  Mild, less common AEs (subjective)                                                                            Anxiety                                                                                                    300.00, 300.09
  Arthralgia                                                                                                    719.4X                                                                                                     
  Asthma/bronchospasm (wheezing)                                                                                519.11, 493.01, 493.02, 493.11, 493.12, 493.21, 493.22, 493.91, 493.92                                     
  Chest pain                                                                                                    786.5                                                                                                      
  Chills                                                                                                        780.64                                                                                                     
  Cyanosis/hypoxia                                                                                              799.02, 782.5                                                                                              
  Acute diarrhea                                                                                                787.91                                                                                                     
  Dizziness                                                                                                     780.4                                                                                                      
  Dysgeusia                                                                                                     781.1                                                                                                      
  Dyspnea                                                                                                       786.05                                                                                                     
  Peripheral edema                                                                                              782.3                                                                                                      
  Emesis                                                                                                        787.0, 787.01, 787.03, 787.04                                                                              
  Fainting                                                                                                      780.2                                                                                                      
  Flushing                                                                                                      782.62                                                                                                     
  Back pain                                                                                                     724.2, 724.5                                                                                               
  Pain                                                                                                          338.1, 338.19                                                                                              
  Palpitation                                                                                                   R00.2                                                                                                      
  Tremor                                                                                                        333.1                                                                                                      
  Urticaria                                                                                                     708.0, 708.1, 708.8, and 708.9                                                                             
  Vertigo                                                                                                       780.4                                                                                                      
  Rigors/shivering                                                                                              780.99                                                                                                     
  Acrodynia                                                                                                     985                                                                                                        
  Colitis/enterocolitis                                                                                         555.XX, 558.2, 558.3, 558.9                                                                                
  Eczematous dermatitis                                                                                         692.9, 693.0                                                                                               
                                                                                                                Sleep disturbance                                                                                          780.5X
  Local reaction -- swelling                                                                                    782.2, 782.8                                                                                               
  Erythema multiforme                                                                                           695.10, 695.11, 695.12, 695.19                                                                             
  Uveitis                                                                                                       360.11, 360.12                                                                                             
  Cutaneous vasculitis (in type II mixed cryoglobulinemia)                                                      709.8                                                                                                      
  Mild, less common AEs (objective)                                                                             Hyperglycemia (glucose-containing products only)                                                           790.29
  Hypotension                                                                                                   458.XX                                                                                                     
  Hypertension                                                                                                  401.X, 405.X, 997.91                                                                                       
  Leucopenia/neutropenia/pancytopenia                                                                           288.03, 284.01, 284.09. 284.81, 284.9, 288.03, 288.5                                                       
  Tachycardia/sinus tachycardia/SVT/arrhythmia (cardiac, any type)                                              785.0, 785.1, 427.XX                                                                                       
  Complement consumption associated with an eczematous cutaneous reaction                                       693                                                                                                        
  Fluid overload                                                                                                276.61, 276.69                                                                                             
  Hyponatremia/hypernatremia                                                                                    276.0, 276.1                                                                                               
  Hematuria                                                                                                     599.7X                                                                                                     
  Coombs positivity (hemolytic anemia)/hemolysis/hemolytic anemia                                               283.XX, 790.01                                                                                             
  Nonspecific elevation of levels of transaminase or LDH                                                        790.4                                                                                                      

**Abbreviations:** URI, Upper respiratory infections; AEs, adverse events; SVT, supraventricular tachycardia; LDH, lactic acid dehydrogenase.
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###### 

Baseline characteristics of study population before and after propensity score matching

  Characteristics                                                              Before   After                                                                                                             
  ---------------------------------------------------------------------------- -------- ------------------ -------- ------------------ ---------- -------- ------------------ -------- ------------------ -------
  **Age (years), mean (95% CI)**                                               47       (45.1--48.9)       47.5     (47--48.1)         0.631      46.4     (44.4--48.5)       48.3     (47.3--49.4)       0.112
  **Age group (years), n (%)**                                                                                                         0.011                                                              0.653
  0--18                                                                        22       8%                 497      12.4%                         22       9.1%               70       7.2%               
  19--30                                                                       21       7.7%               244      6.1%                          19       7.9%               68       7%                 
  31--54                                                                       123      44.9%              1,475    36.8%                         107      44.2%              421      43.5%              
  ≥55                                                                          108      39.4%              1,794    44.7%                         94       38.8%              409      42.3%              
  **Male, n (%)**                                                              126      46%                1,799    44.9%              0.718      110      45.5%              436      45%                0.908
  **Census region, n (%)**                                                                                                             \<0.0001                                                           0.968
  Northeast                                                                    147      53.6%              816      20.3%                         115      47.5%              449      46.4%              
  Midwest                                                                      49       17.9%              1,304    32.5%                         49       20.2%              191      19.7%              
  South                                                                        62       22.6%              1,596    39.8%                         62       25.6%              263      27.2%              
  West                                                                         16       5.8%               294      7.3%                          16       6.6%               65       6.7%               
  **Proximity to centers, n (%)**                                              217      79.2%              2,432    60.6%              \<0.0001   185      76.4%              761      78.6%              0.465
  **Autoimmune disease, n (%)**                                                                                                        0.002                                                              1.000
  IVIG-treatable                                                               169      66.5%              2,067    55.3%                         145      63%                580      63%                
  Not IVIG-treatable                                                           11       4.3%               218      5.8%                          11       4.8%               44       4.8%               
  Not autoimmune immunodeficiency[a](#tfn1-ceor-10-001){ref-type="table-fn"}   74       29.1%              1,456    38.9%                         74       32.2%              296      32.2%              
  **CCI scores, n (%)**                                                                                                                0.003                                                              0.748
  0                                                                            94       34.3%              1,032    25.7%                         81       33.5%              339      35%                
  1--2                                                                         122      44.5%              1784     44.5%                         108      44.6%              414      42.8%              
  3--4                                                                         36       13.1%              768      19.2%                         31       12.8%              141      14.6%              
  ≥5                                                                           22       8%                 426      10.6%                         22       9.1%               74       7.6%               
  **6-month pre-index total health care costs, mean US\$ (95% CI)**            47,961   (38,310--57,612)   53,731   (50,805--56,657)   0.324      48,552   (38,051--59,053)   52,339   (46,190--58,487)   0.578
  **Categorical costs, n (%)**                                                                                                         0.224                                                              0.828
  ≤\$15,000                                                                    72       26.3%              1,120    27.9%                         63       26%                253      26.1%              
  \>\$15,000--≤\$30,000                                                        76       27.7%              988      24.6%                         64       26.4%              247      25.5%              
  \>\$30,000--≤\$60,000                                                        74       27%                963      24%                           68       28.1%              255      26.3%              
  \>\$60,000                                                                   52       19%                939      23.4%                         47       19.4%              213      22%                

**Note:**

Including common variable immunodeficiency.

**Abbreviations:** CCI, Charlson Comorbidity Index; IVIG, intravenous immunoglobulin.

###### 

Infection and adverse event rates of comparison groups

  Clinical outcomes                Rates (events/patient/year)[a](#tfn3-ceor-10-001){ref-type="table-fn"}   Proportion of patients (% of patients)                                      
  -------------------------------- ------------------------------------------------------------------------ ------------------------------------------------- ------- -------- -------- -------
  **Infections**                                                                                                                                                                        
  All                              2.71                                                                     2.06                                              0.274   54.13%   53.2%    0.795
  Serious bacterial                0.12                                                                     0.45                                              0.066   4.13%    7.75%    0.049
  Other                            2.52                                                                     1.85                                              0.241   52.89%   50.31%   0.472
  **Adverse events**                                                                                                                                                                    
  Common                           0.02                                                                     0.03                                              0.776   1.65%    2.69%    0.355
  Serious                          0.02[b](#tfn4-ceor-10-001){ref-type="table-fn"}                          0.01[b](#tfn4-ceor-10-001){ref-type="table-fn"}   NA      1.65%    0.62%    0.12
  Mild, less common (subjective)   0.04                                                                     0.03                                              0.333   3.72%    4.13%    0.771
  Mild, less common (objective)    NA                                                                       NA                                                NA      9.92%    7.23%    0.163

**Notes:**

Rates are means after adjustment of program management model, number of Ig administrations, site of care, diabetes (yes/no), and renal disease (yes/no) by the GEE regression model;

unadjusted means, since the GEE model did not converge.

**Abbreviations:** GEE, generalized estimation equation; NA, not applicable.

###### 

Total allowable costs (US\$) of comparison groups

  Total allowable costs[a](#tfn6-ceor-10-001){ref-type="table-fn"}   Intervention   Control                 *P*         Mean difference, \[A\] -- \[B\]           
  ------------------------------------------------------------------ -------------- ----------------------- ----------- --------------------------------- ------- ----------
  Total costs                                                        \$109,476      (\$98,568--\$121,592)   \$135,998   (\$121,766--\$151,893)            0.002   \$26,522
   Ig-related                                                        \$64,332       (\$57,926--\$71,447)    \$81,827    (\$73,127--\$91,562)              0.001   \$17,495
  Total inpatient costs                                              \$8,781        (\$5,171--\$14,912)     \$14,137    (\$7,767--\$25,732)               0.236   \$5,356
  Total EC costs                                                     \$992          (\$558--\$1,764)        \$482       (\$293--\$793)                    0.107   \$510
  Total outpatient costs                                             \$93,865       (\$84,858--\$103,827)   \$108,561   (\$97,899--\$120,384)             0.026   \$14,696
   Ig-related                                                        \$64,080       (\$57,656--\$71,219)    \$81,349    (\$72,646--\$91,094)              0.001   \$17,269
  Total pharmacy costs                                               \$6,666        (\$5,313--\$8,363)      \$8,183     (\$6,287--\$10,651)               0.189   \$1,517

**Note:**

Mean costs per patient per year are means after adjustment of program management model, site of care, and number of Ig administrations by regression model.

**Abbreviation:** EC, emergency center.
